BSF Enterprise secures £1m convertible loan note from Indigo Capital
What's the deal? BSF EnterpriseDealroom has a profile for this one. Try Dealroom →, a developer of tissue-engineered materials, has secured a £1 million convertible loan note from Indigo CapitalDealroom has a profile for this one. Try Dealroom → LP. The interest-free facility has a 12-month term and will give the London-listed company additional working capital as it pushes forward commercial and product development work.
BSF's portfolio spans lab-grown leather, cultivated meat, and corneal repair technologies.
The conversion price is set at 85% of the lowest five-day volume-weighted average price before a conversion notice, and any unconverted balance will convert at maturity. BSF can redeem outstanding notes at 125% of nominal value. Indigo will also receive warrants over 9.8 million ordinary shares, exercisable for two years at 3.57p.
Why now? Chairman Geoff Baker said the funding provides "additional working capital and financial flexibility" as BSF develops commercial opportunities across its tissue-engineered product portfolio. The company appears to be at an inflection point where it needs capital to bridge the gap between R&D and commercialisation.
What could go wrong? Convertible loan notes with discount-to-market conversion terms can be dilutive for existing shareholders, especially if the share price drops. The 85% conversion discount means Indigo is guaranteed a built-in gain on conversion, which could pressure the stock.
Tissue engineering remains a nascent industry with long development timelines and uncertain regulatory paths — particularly for cultivated meat, which faces varying rules across jurisdictions.
The signal: BSF Enterprise remains firmly at the early stage, according to Dealroom, operating across lab-grown leather, cultivated meat, and corneal repair — three verticals with very different commercialisation timelines. That the funding came via a convertible loan note from a corporate investor rather than a traditional equity raise suggests limited options for a company still bridging the gap between science and revenue.
Read more: Proactive Investors
